Transarterial chemoembolisation enhances programmed death-1 and programmed death ligand-1 expression in hepatocellular carcinoma

被引：0
|
作者：
Montasser, A. [1 ,2 ]
Beaufrere, A. [1 ,3 ]
Cauchy, F. [4 ]
Soubrane, O. [4 ]
Colnot, N. [1 ]
Tessiore, S. [1 ]
Albuquerque, M. [1 ,3 ]
Paradis, V. [1 ,3 ]
机构：
[1] Beaujon Univ Hosp, AP HP, Dept Pathol, Clichy, France
[2] Theodor Bilharz Res Inst, Dept Pathol, Giza, Egypt
[3] Beaujon Univ Hosp, INSERM, U1149, Clichy, France
[4] Beaujon Univ Hosp, AP HP, Dept HPB & Pancreat Surg, Clichy, France
来源：
VIRCHOWS ARCHIV | 2019年 / 475卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-05-004
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [21] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns Reply
    Naidoo, Jarushka
    Iyriboz, Tunc
    Cunningham, Jane
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1629 - +
  • [22] Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
    Zhang, Yan
    Li, Jinbao
    Lou, Jingsheng
    Zhou, Ying
    Bo, Lulong
    Zhu, Jiali
    Zhu, Keming
    Wan, Xiaojian
    Cai, Zailong
    Deng, Xiaoming
    [J]. CRITICAL CARE, 2011, 15 (01):
  • [23] Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
    Zhang, Ni
    Tu, Jingyao
    Wang, Xue
    Chu, Qian
    [J]. IMMUNOTHERAPY, 2019, 11 (05) : 429 - 441
  • [24] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    [J]. BLOOD, 2018, 132
  • [25] Clinical significance and therapeutic potential of programmed death 1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Nichiporuk, E.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A. M.
    [J]. ONKOLOGIE, 2008, 31 : 80 - 80
  • [26] Programmed death-1 expression in breast carcinoma
    Zafar, S.
    Kayani, N.
    Usman, M.
    [J]. HISTOPATHOLOGY, 2022, 81 : 24 - 25
  • [27] Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
    Zhang, Ying
    Zhu, Weipei
    Zhang, Xueguang
    Qu, Qiuxia
    Zhang, Liyuan
    [J]. ONCOLOGY LETTERS, 2017, 14 (06) : 7225 - 7231
  • [28] Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
    Chen, Zhifang
    Pang, Nannan
    Du, Rong
    Zhu, Yuejie
    Fan, Lingling
    Cai, Donghui
    Ding, Yan
    Ding, Jianbing
    [J]. MEDIATORS OF INFLAMMATION, 2016, 2016
  • [29] The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma
    Al-Jussani, Ghada N.
    Alsughayer, Anas
    Yousuf, Mustafa S.
    Mullahuwash, Yaseen
    Dabbagh, Tamara
    Sughayer, Maher A.
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2022, 37 (03): : 322 - 327
  • [30] Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis
    Chakravarti, Nitin
    Prieto, Victor G.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 743 - 751
12345